Characteristics | Dose level | |||
---|---|---|---|---|
1 | 2 | 3 | Total | |
Number of patients | 4 (100%) | 13 (100%) | 7 (100%) | 24 (100%) |
Age, years | ||||
N | 4 | 13 | 6 | 23 |
Median (range) | 55.5 (38–75) | 65.0 (33–70) | 56.0 (44–63) | 62.0 (33–75) |
Gender, n (%) | ||||
Female | 1 (25%) | 2 (15%) | 3 (13%) | |
Male | 3 (75%) | 11 (85%) | 7 (100%) | 21 (88%) |
KPS | ||||
N | 3 | 12 | 7 | 22 |
Median (range) | 100 (100–100) | 90 (90–100) | 100 (90–100) | 95 (90–100) |
Siewert classification | ||||
AEG II | 2 (50%) | 9 (69%) | 7 (100%) | 18 (75%) |
AEG III | 2 (50%) | 4 (31%) | 6 (25%) | |
T staging | ||||
3 | 3 (75%) | 10 (77%) | 6 (86%) | 19 (79%) |
4 | 1 (25%) | 2 (15%) | 1 (14%) | 4 (17%) |
X | 1 (8%) | 1 (4%) | ||
N staging | ||||
0 | 2 (15%) | 2 (8%) | ||
1 | 2 (50%) | 5 (38%) | 4 (57%) | 11 (46%) |
2 | 2 (50%) | 4 (31%) | 2 (29%) | 8 (33%) |
X | 2 (15%) | 1 (14%) | 3 (13%) | |
M staging | ||||
0 | 3 (75%) | 12 (92%) | 7 (100%) | 22 (92%) |
X | 1 (25%) | 1 (8%) | 2 (8%) | |
UICC staging | ||||
II A | 2 (15%) | 2 (8%) | ||
III | 4 (100%) | 8 (62%) | 6 (86%) | 18 (75%) |
NK | 3 (23%) | 1 (14%) | 4 (17%) |